Wealthspring Capital’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Wealthspring Capital’s Portfolio ORIAU Stock Details ORIAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-98,690	Closed	-$972K	–	364
2022 Q3	$972K	Sell	98,690 -4,000	-4%	-$39.4K	0.19%	189
2022 Q2	$997K	Sell	102,690 -2,000	-2%	-$19.6K	0.19%	193
2022 Q1	$1.02M	Sell	104,690 -1,220	-1%	-$12K	0.2%	185
2021 Q4	$1.03M	Sell	105,910 -7,000	-6%	-$69.6K	0.22%	170
2021 Q3	$1.12M	Buy	112,910 +4,000	+4%	+$40K	0.27%	132
2021 Q2	$1.09M	Buy	+108,910	New	+$1.1M	0.27%	121

Other funds holding ORIAU

JNE Partners London, United Kingdom $244M AUM 15.73% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

GAM

Gritstone Asset Management Bethesda, Maryland $93.6M AUM 11.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wealthspring Capital's ORIAU Position: Q4 2022 in Review

Wealthspring Capital sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q4 2022, closing a stake of 98,690 shares — an estimated $972K sold.

Wealthspring Capital first reported a position in ORIAU in Q2 2021 and held it in 6 quarters. The position peaked at $1.12M in Q3 2021. 6 funds tracked by Wall St. Rank hold ORIAU as of Q4 2022.

Wealthspring Capital reported no remaining Orion Biotech Opportunities Corp. Units position as of Q4 2022 after selling out during the quarter.
Wealthspring Capital sold 98,690 Orion Biotech Opportunities Corp. Units shares in Q4 2022, an estimated $972K.
Wealthspring Capital first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 6 quarters.
Wealthspring Capital's Orion Biotech Opportunities Corp. Units position peaked at $1.12M in Q3 2021.
6 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q4 2022.

Based on Wealthspring Capital's 13F filing for Q4 2022, filed 8 Feb 2023.